Trial Profile
A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KESTREL
- Sponsors AstraZeneca; AstraZeneca AB
- 02 Mar 2024 Results investigating independent biomarkers for association with efficacy, published in the Cancer Immunology Immunotherapy
- 04 Oct 2023 Results presented in the Institute of Cancer Research media release.
- 16 Dec 2022 Results published in the Annals of Oncology